

Acute lymphoblastic leukaemia (ALL) trial XII (joint trial with Eastern Co-operative Oncology Group - E2993)

Submission date 25/10/2000	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 25/10/2000	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 21/10/2009	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

<http://www.ctsu.ox.ac.uk/projects/leuk/ukallxii/new-4th-dec-2006/ukallxii-protocol-version-5-0.pdf>

Contact information

Type(s)

Scientific

Contact name

Professor A Goldstone

Contact details

University College Hospital
Gower Street
London
United Kingdom
WC1E 6AU

Additional identifiers

EudraCT/CTIS number

2005-006181-31

IRAS number

ClinicalTrials.gov number

NCT00002514

Secondary identifying numbers

G8223452, MREC/02/2/84

Study information

Scientific Title

Acronym

UKALLXII

Study objectives

1. To compare effects of marrow ablative therapy using VP16 and total body irradiation followed by autologous bone marrow rescue (ABMT or Peripheral Stem Cell Rescue) with conventional consolidation and maintenance chemotherapy in adult patients between 15 and 55 years who have no HLA compatible donor
2. To examine (in a non-randomised study) differences in outcome in adult ALL in those patients who have an HLA compatible donor, who will be allocated allogeneic BMT versus those with a donor randomised to autologous BMT or conventional chemotherapy
3. To compare the outcome of the above three treatments or matched unrelated donor BMT in patients with Philadelphia chromosome positive disease and to examine the efficacy of additional Interferon during maintenance chemotherapy or after BMT

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Leukaemia

Interventions

1. Marrow ablative therapy using VP16 and total body irradiation followed by autologous bone marrow rescue (ABMT or Peripheral Stem Cell Rescue)
2. Conventional consolidation and maintenance chemotherapy

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

1. Length of survival
2. Relapse rates

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/01/1993

Completion date

30/09/2008

Eligibility**Key inclusion criteria**

1. Adult patients between 15 and 55 years with previously untreated ALL
2. Morphological proof of ALL
3. Diagnosis has been made from bone marrow morphology with greater than 25% lymphoblasts by the French-American-British (FAB) criteria

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

550

Key exclusion criteria

1. Prior malignancy for which chemotherapy or radiotherapy have been given
2. AML, MDS or other antecedent haematological disorder or lymphoid transformation of chronic myeloid leukaemia

3. Previously treated
4. Intercurrent life threatening disease
5. Pregnant or lactating

Date of first enrolment

01/01/1993

Date of final enrolment

30/09/2008

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

University College Hospital

London

United Kingdom

WC1E 6AU

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

<http://www.mrc.ac.uk>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/07/2006		Yes	No
Results article	results	01/03/2007		Yes	No
Results article	results on prospective outcome data	07/05/2009		Yes	No
Results article	results on clinical and biological features of participants	10/12/2009		Yes	No